End-of-day quote
Shenzhen S.E.
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
4.46
CNY
|
+4.69%
|
|
-8.42%
|
-30.31%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,756
|
2,249
|
8,470
|
9,082
|
5,409
|
3,915
|
Enterprise Value (EV)
1 |
1,793
|
2,302
|
9,771
|
9,013
|
5,805
|
4,664
|
P/E ratio
|
21.1
x
|
16
x
|
29.1
x
|
54.8
x
|
58.8
x
|
80
x
|
Yield
|
-
|
1.59%
|
1.46%
|
-
|
1.36%
|
1.25%
|
Capitalization / Revenue
|
0.12
x
|
2.51
x
|
0.62
x
|
4.7
x
|
3.03
x
|
2.54
x
|
EV / Revenue
|
0.13
x
|
2.57
x
|
0.71
x
|
4.67
x
|
3.25
x
|
3.02
x
|
EV / EBITDA
|
7.87
x
|
7.58
x
|
18
x
|
29.6
x
|
17.3
x
|
28.7
x
|
EV / FCF
|
-53.4
x
|
-57.8
x
|
-27.6
x
|
11.1
x
|
-15.5
x
|
106
x
|
FCF Yield
|
-1.87%
|
-1.73%
|
-3.62%
|
9.03%
|
-6.43%
|
0.95%
|
Price to Book
|
1.18
x
|
2.5
x
|
3.23
x
|
3.5
x
|
2.01
x
|
1.47
x
|
Nbr of stocks (in thousands)
|
238,000
|
238,000
|
618,223
|
614,084
|
613,223
|
611,689
|
Reference price
2 |
7.380
|
9.450
|
13.70
|
14.79
|
8.820
|
6.400
|
Announcement Date
|
3/29/19
|
4/28/20
|
4/27/21
|
4/13/22
|
4/25/23
|
4/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
14,335
|
896.4
|
13,702
|
1,931
|
1,786
|
1,542
|
EBITDA
1 |
227.8
|
303.6
|
543.6
|
304.3
|
335.5
|
162.5
|
EBIT
1 |
158.7
|
265.4
|
438.1
|
210.7
|
232.6
|
70.19
|
Operating Margin
|
1.11%
|
29.61%
|
3.2%
|
10.91%
|
13.02%
|
4.55%
|
Earnings before Tax (EBT)
1 |
143.2
|
249.5
|
347.8
|
361.1
|
100.1
|
29.93
|
Net income
1 |
84.08
|
210.8
|
284.9
|
166.5
|
93.88
|
49.21
|
Net margin
|
0.59%
|
23.51%
|
2.08%
|
8.62%
|
5.26%
|
3.19%
|
EPS
2 |
0.3500
|
0.5900
|
0.4700
|
0.2700
|
0.1500
|
0.0800
|
Free Cash Flow
1 |
-33.58
|
-39.83
|
-353.9
|
813.6
|
-373.4
|
44.08
|
FCF margin
|
-0.23%
|
-4.44%
|
-2.58%
|
42.14%
|
-20.9%
|
2.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
267.4%
|
-
|
27.13%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
488.6%
|
-
|
89.57%
|
Dividend per Share
|
-
|
0.1500
|
0.2000
|
-
|
0.1200
|
0.0800
|
Announcement Date
|
3/29/19
|
4/28/20
|
4/27/21
|
4/13/22
|
4/25/23
|
4/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
36.8
|
52.6
|
1,301
|
-
|
397
|
749
|
Net Cash position
1 |
-
|
-
|
-
|
69.5
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.1616
x
|
0.1734
x
|
2.393
x
|
-
|
1.183
x
|
4.612
x
|
Free Cash Flow
1 |
-33.6
|
-39.8
|
-354
|
814
|
-373
|
44.1
|
ROE (net income / shareholders' equity)
|
7.53%
|
25.9%
|
10.3%
|
5.75%
|
2.67%
|
0.94%
|
ROA (Net income/ Total Assets)
|
4.01%
|
13.7%
|
5.08%
|
2.62%
|
3.39%
|
1.03%
|
Assets
1 |
2,096
|
1,543
|
5,605
|
6,344
|
2,773
|
4,776
|
Book Value Per Share
2 |
6.270
|
3.780
|
4.240
|
4.230
|
4.380
|
4.340
|
Cash Flow per Share
2 |
2.090
|
0.5500
|
0.9300
|
1.490
|
0.7600
|
0.3700
|
Capex
1 |
200
|
113
|
559
|
286
|
167
|
129
|
Capex / Sales
|
1.39%
|
12.6%
|
4.08%
|
14.79%
|
9.36%
|
8.35%
|
Announcement Date
|
3/29/19
|
4/28/20
|
4/27/21
|
4/13/22
|
4/25/23
|
4/25/24
|
|
1st Jan change
|
Capi.
|
---|
| -30.31% | 376M | | +20.04% | 43.3B | | +23.67% | 22.22B | | +15.96% | 15.43B | | +23.14% | 14.48B | | +57.57% | 12.72B | | -0.05% | 6.79B | | -10.69% | 6.71B | | -8.87% | 5.73B | | +14.68% | 5.5B |
Generic Pharmaceuticals
|